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B S T R A C T

Background: Since COVID-19 was declared a pandemic in March 2020, hospitals and
patient care facilities have faced challenges in protecting healthcare workers and patients
from being exposed to the infection. The main challenge has been how exposure to COVID19 can be controlled when asymptomatic patientscan transmit the infection. This study
aims to evaluate pre-admission testing of COVID-19 in patients at the Aga Khan University
Hospital, Nairobi as a screening strategy for understanding, preventing and controlling
exposure to COVID-19.
Methods: This was a descriptive retrospective chart review study that analysed the
incidence of COVID-19, incidental detection of laboratory-confirmed COVID-19 and effects
on plan of care in patients prior to admission at the Aga Khan University Hospital from April
to December 31, 2020. Demographic data, clinical characteristics, COVID-19 test report
and plan of care were retrieved from patients medical records review.
Results: A total of 8837 pre-admission tests were done between April 2020 and December
2020, with a COVID-19 prevalence rate of 10.9% (961/8837). Among the positive preadmission tests, 14.3% were incidental positive results (138/961). Among the 138 incidental positive tests 21% (30) had their plan of care affected, 14.5% [20] had their care
interventions delayed, 4.3% [6] had their hospital stay shortened, 1.4% [2] their hospital
stay prolonged and 0.7% [1] had their care diagnostics delayed.
Conclusion: While community spread of COVID-19 fluctuated during this period; depending
on the level of compliance to infection control measures, pre-admission prevalence rates
were increasing as the year progressed. Mandatory testing of COVID-19 in hospital facilities
remains an important admission requirement in controlling asymptomatic transmission of
the virus. COVID-19 health burden justifies resource allocation for universal screening of
all patients before hospital admission.
ª 2022 The Authors. Published by Elsevier Ltd
on behalf of The Healthcare Infection Society. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
COVID-19 was declared a pandemic in March 2020, after it
was first identified in December 2019 in Wuhan, China. Since
then, hospitals and patient care facilities have faced challenges in promptly identifying infected patients being admitted
in hospitals [1]. The reproduction rate of COVID-19 infection
has been estimated to be 2.24 to 3.58, however the numbers
may vary with mobility, containment measures, individual
susceptibility and population at risk [2]. Identification of cases
became more challenging after World Health Organization
(WHO) revised its guidelines on how SARS COV-2 is transmitted
by airborne spread and asymptomatic transmission [3]. Transmission of COVID-19 by asymptomatic individuals has been
approximated to account for 40%e45% of infections, which
justifies the inclusion of individuals without symptoms in

testing programs for SARS-COV-2 [4]. Asymptomatic transmission of COVID-19 has been demonstrated in a study at a
London teaching hospital, where 15% of COVID-19 infections
admitted between March and April were reported to have been
infected while in the hospital [5].
With the emergence of COVID-19, communicable disease
screening using symptoms may not be enough in identifying
potentially infected cases because there is a significant chance
of cases being asymptomatic [6]. Misdiagnosis is highly likely
for patients without symtoms of COVID-19 and one would
require additional vigilance to accurately suspect a case [7e9].
It is also noted that the risk of infection is increased where
people are overcrowded in enclosed spaces [10]. A study in
Wuhan showed how crowded emergency rooms promoted
transmission of COVID-19 to people who were wearing masks
that were inferior to N95 [11].

Figure 1. Flowchart of study methodology.
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Despite having several testing strategies for COVID-19, the
gold standard for testing COVID-19 clinical cases remains
nucleic acid detection techniques, like RT-PCR [12]. Asymptomatic transmission of COVID-19 has further challenged
efforts to control nosocomial infections, necessitating universal testing for SARS-COV-2 in all patients being admitted [13]. In
the United Kingdom, universal screening using COVID-19 PCR is
now advised for every patient admitted to hospital due to high
prevalence of COVID-19 in the community [14]. The preadmission testing strategy has significantly improved workforce depletion due to unnecessary quarantine and controlled
potential transmission of COVID-19 infection by asymptomatic
patients [15].
In Africa, the first case of COVID-19 was first confirmed in
Egypt on February 14, 2020. The continent’s level of preparedness strongly depended on the application and execution of
testing measures for COVID-19 [16]. The first case reported in
Kenya was on March 13, 2020, and the number of confirmed
cases has continually increased. By June 2020, the populationweighted test-performance-adjusted national seroprevalence
was 4.3%, which was lower than the actual exposure of 5.6% by
a study conducted on SARS-CoV-2 Immunoglobulin G among
blood donors [17]. At some point, Kenya’s Ministry of Health
(MoH) embarked on mass testing but faced challenges of test
kit shortages because of high global demand, human resources,
and logistical challenges which negatively affected the
response towards controlling COVID-19 [18].
The Aga Khan University Hospital, Nairobi (AKUHN), adopted
mandatory PCR testing of the nasopharyngeal swab for all
patients admitted at the beginning of April 2020 as an additional strategy to diagnosing COVID-19. The AKUHN admitted
its first confirmed COVID-19 patient on March 22, 2020.
COVID-19 diagnosis has also resulted in delays in patient
care, early discharge from hospital, or a change in care management [19]. This study aims to evaluate pre-admission testing of COVID-19 in patients at the Aga Khan University Hospital,
Nairobi as a screening strategy for understanding, preventing
and controlling exposure to COVID-19. And controlling exposure
to COVID-19.
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Methods
This was a descriptive retrospective chart review study for
COVID-19 patients who were tested during hospital admission
at AKUHN. Extracted data contained pre-admission COVID-19
test results, presenting complaint, incidental COVID-19 (a
positive COVID-19 test that was unexpected based on clinical
features) and its effect on care. This study was approved by the
Institutional Ethics Review Committee at AKUHN and National
Commission for Science, Technology and Innovation (NACOSTI).
The data extracted was limited to information that was specific
to the aims. Patient identifiers in the data were removed and
extracted data was stored in an excel sheet and password
protected to ensure confidentiality and integrity.
Summary statistics was presented as frequencies and percentages or means and standard deviations. Univariate analysis
was performed using Chi-squared tests or Kruskal Wallis test.
Logistic regression was also used and odds ratios were presented
with 95% confidence intervals. The statistical significance was
considered at the P-value of <0.05, and all the statistical tests
were performed using IBM SPSS Version 23.0.

Results
A total of 8,837 pre-admission tests were done between
April 2020 and December 2020, with a COVID-19 prevalence
rate of 10.9% (961/8837) (Fig. 1). Of the 961 positive tests, 639
(66.5%, 639/961) were males and majority of the cases
(621,64.6%, 621/961) were between 31- 60 years old. Incidental COVID-19 test results accounted for 14.2% (136/961) of
the total positive tests and 1.5% (136/8837) of the total preadmission COVID-19 tests. The plan of care was affected in
22% (30/136) of patients whose COVID-19 positive tests were
incidental while care diagnostics and interventions were
delayed in 0.7% (1/136) and 14.7% (20/136) respectively in
patients that had asymptomatic COVID-19. As for hospital stay,
4.4% (6/136) of the patients’ hospital stay was shortened and
1.5% (2/136) prolonged. The prevalence rate of positive COVID19 tests at admission for males and females was 7.2% (639/

COVID-19 Admissions by Age and Gender in 2020
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8837) and 3.6% (322/8837) respectively. There was an increase
in the overall prevalence rate over time, 8.6% (123/1430) in
April to june, 10.4% (380/3650) in July to September and 12.2%
(458/3757) in October to December. The mean age of positive
tests was 50.1 years (SD¼13.5), males (mean 51.5 years;
SD¼15.7) and females (mean 47.2 years; SD¼17.1) The distribution of age and gender is presented in Figure 2. Gender
was associated with COVID-19 symptoms, where only 9% (55/
639) of the males were incidental positive, compared to 25%
(81/322) of females (P <0.001). Age distribution was also
associated with COVID-19 symptoms. The association of gender
and age with COVID-19 symtoms is shown in Table 1.
The mean age of females with COVID-19 was lower as compared to the males and was statistically significant; (Females:
46.99 years (SD¼17.1) vs Males: 51.52 years (SD¼15.71); P
<0.001).
The mean age of incidental COVID-19 was lower as compared to non-incidental COVID-19 and was statistically significant (Incidental: 39.88 years (SD¼17.9) vs Non-Incidental:
51.67 years (SD¼15.43); P <0.001) (Table 2).
Based on logistic regression, the odds of having incidental
COVID-19 infection was significantly higher in both 0e30 years
and 31e60 years as compared to >60 years (reference).
Regarding gender, females were more likely to have incidental
COVID-19 compared to males. Table 3 presents the results of
the logistic regression.

Discussion
In this study, the prevalence rate of 10.9% (961/8837) is
higher than the earlier reported rates in two surveys that
showed a national seroprevalence rate of 4.3% by populationweighted, test-performance-adjusted and 5.6% from actual
exposure on Immunoglobulin G among blood donors [17]. The
difference of these rates can be explained by the duration and
point of time the surveys were done. The Pprevalence rate
from this study was over several months during which two
wavesof infections occurred. Overall COVID-19 numbers were
higher in males, however the numbers were similar for those
who were between 31 and 60 years. This was different to other
findings which indicated that females below age 35 years had
higher chances of getting infected than males in the same age
category [20]. Over the review period, the prevalence rates for
positive COVID-19 tests at admission for males and females
were 7.2% (639/8837) and 3.6% (322/8837) respectively. For
tests that were positive, 14% (136/961) were incidental positive results. To understand the pandemic, use of percentages

Table 1
Association with COVID-19 symptom status.
Characteristics

Gender
Male
Female
Age (years)
1e30 years
31e60 years
>60 years

Symptomatic
positive PCR

N (825)
584 (91%)
241 (75%)

Incidental positive PCR

N (136)
55 (9%)
81 (25%)

P Value

<0.001

Table 2
Association of age by gender and incidental COVID-19.
Characteristics

Gender
Male
Female
Incidental COVID-19
Yes
No

31 (34.4%)
87 (14.0%)
18 (7.2%)

Std

P Value

51.52
46.99

15.714
17.098

<0.001

39.88
51.67

17.899
15.434

<0.001

in estimating the rates of infection is more relevant using
actual numbers [21]. Asymptomatic patients who tested positive for COVID-19 accounted for 1% (136/8837) of the total
patients who had a preadmission test for COVID-19 between
March 2020 and December 2020.
More females than males had incidental COVID-19, 59% (81/
136) and accounted for 25% (81/322) of the total positive tests
for females likely explained by a higher number of females
being admitted are of childbearing age, incidental positive
tests seen mostly in women who came in during labour. The
chances of getting infected with COVID-19 may vary among
gender and different age categories. This study explores age
categories and found that persons aged between 30 to 60 years
65.5% (621/961) were seven times likely to be admitted with
COVID-19 as compared to ages between 0 to 30 years 9.5% (90/
961). This finding is consistent with a previous study that
indicated COVID-19 infection rates were low in persons with
lower age category [22]. Other findings also indicate that all
age groups are equally susceptible to SARS-CoV-2 infection but
that the symptomatic rate is different across age groups (23).
Variations in infection rates and symptomatic COVID-19 disease
across age and gender may further be explained by biological
variations. Currently, less testing is being done in developing
countries.. With regard to age, earlier evidence indicated that
the older population were at higher risk of infection. However,
since around mid-May and early-June 2020, younger people are
increasingly being infected with the virus leading to a high rate
of hospitalisation and isolation worldwide [22]. There was also
significant effect on planned care following diagnosis of incidental COVID-19; with 22% (30/136) of incidental results cases
having interruption of care.
Results from this study justify mandatory pre-testing of
patients before admission as a significant measure of prevention and control of SARS CoV-2 infection transmission in
hospital settings. The findings can also be used to estimate the
prevalence rates of COVID-19 in the community. This is a single
centre study, another limitation is that the nature of the data

Table 3
Binary logistic regression model for age categories and gender as
the predictor for incidental COVID-19.
Factors

<0.001
59 (65.6%)
534 (86.0%)
232 (92.8%)

Mean age

0e30 years
31e60 years
Female

P-value

<0.001
0.006
0.000

O.R

6.77
2.10
3.57

95% CI. for O.R.
Lower

Upper

3.54
1.23
2.45

12.94
3.56
5.19
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keeps changing. The trends of this study may have since
changed because of vaccination developments, and so the
interpretation of this study should apply to March 22 to
December 31, 2020 period. Also new testing for COVID-19 with
a shorter turnaround time are being adapted for preadmission
screening although PCR test for SARS-COV-2 still remains the
gold standard.
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